Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this
conference was to develop an expert consensus-driven working framework for …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …

Abstract Enzalutamide (MDV3100, Xtandi, Medivation\Astellas) is an oral inhibitor of
androgen receptor signaling that blocks androgen receptor interaction, inhibits translocation …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis,
evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract …

Background Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy is the
standard of care for muscle-invasive bladder cancer (MIBC), with 25–50% of patients …

Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …

Purpose Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive
bladder cancer (MIBC); however, it is infrequently adopted in practice because of concerns …